<--- Back to Details
First PageDocument Content
Risk management / Risk factors / Actuarial science / Aging-associated diseases / Evaluation / Risk assessment / BRCA mutation / Breast cancer / Cancer / Risk / Management / Medicine
Date: 2010-06-07 12:57:34
Risk management
Risk factors
Actuarial science
Aging-associated diseases
Evaluation
Risk assessment
BRCA mutation
Breast cancer
Cancer
Risk
Management
Medicine

MyGenerations Communicating Familial Risk

Add to Reading List

Source URL: www.cdc.gov

Download Document from Source Website

File Size: 2,31 MB

Share Document on Facebook

Similar Documents

Cancer / Breast cancer / Health / Clinical medicine / Tumor suppressor genes / Tumor markers / Hereditary cancers / RTT / BRCA mutation / BRCA1 / BRCA2 / Myriad Genetics

Outlaw Human Gene Patents Because Human Genes Belong to Human Beings NOT Corporations. The US Supreme Court is currently considering the question

DocID: 1qIXp - View Document

RTT / Health / Cancer / Clinical medicine / Ovarian cancer / Breast cancer / Smoking / Cigarette / Ovarian Cancer National Alliance / BRCA mutation

ENGLISH SUMMARY Ovarian cancer is the most lethal gynaecologic cancer. Today, there is no population-based screening tool in ovarian cancer and as the disease typically has a vague clinical presentation; most women are d

DocID: 1quQa - View Document

Breast cancer / RTT / Cancer screening / Ribbon symbolism / Hereditary cancers / Breast cancer screening / Mammography / BRCA mutation / BRCA2 / BRCA1 / Breast imaging / Cancer

CNE Objectives and Evaluation Form appear on pageSERIES Deciphering the Diagnostics of Breast Cancer

DocID: 1oQ5n - View Document

Cancer screening / Breast surgery / Cancer / Ovarian cancer / Mammography / Mammary ductal carcinoma / Metastasis / Mastectomy / BRCA mutation / Medicine / Breast cancer / Ribbon symbolism

S P E C I A L A D V E R T I S I N G eauty

DocID: 19JOV - View Document

Tumor markers / Tumor suppressor genes / BRCA mutation / Breast cancer / Lactams / PARP inhibitor / BRCA2 / Ovarian cancer / BRCA1 / Medicine / Oncology / Mutation

ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib Elizabeth Swisher,1 James Brenton,2 Scott Kaufmann,3 Amit Oza,4 Robert L. Coleman,5 David O’Malley,6 Gottfried Ko

DocID: 19bpI - View Document